No Data
No Data
NeuroSense Highlights PARADIGM Clinical Trial Data; Co To Submit 12-Month Data To FDA To Discuss Path Forward
Express News | Neurosense Therapeutics Ltd - Intends to Submit Results to Regulatory Agencies, Including FDA, to Discuss Primec's Path Forward in Short Term
Express News | Neurosense Therapeutics Ltd - Paradigm ALS Clinical Trial Demonstrates up to 73% Improved Complication-Free Survival
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression
Buy Rating Affirmed on Neurosense Therapeutics Following Promising PrimeC Trial Results
This Cheap Biotech Offers Investors a Play on ALS If Trial Data Continues to Impress
No Data